Tribunal Nixes Most of Medtronic Patent for Hypertension Therapy

Otuska Holding Co. subsidiaries convinced an administrative tribunal to invalidate most of a Medtronic Plc patent covering a hypertension treatment after an appeals court revived their challenge.

The majority of US Patent No. 8,845,629 , which protects Medtronic’s Symplicity Spyral Renal Denervation System, is obvious and anticipated in light of prior inventions, the Patent Trial and Appeal Board ruled in an order issued Monday. The patent describes a treatment using heat on veins leading to the kidneys.

The US Court of Appeals for the Federal Circuit in March overturned the board’s 2023 decision upholding the patent’s validity, directing it to ...